Drug markers body says govt's ban 'arbitrary and unfair'

Image
Press Trust of India New Delhi
Last Updated : Mar 18 2016 | 6:57 PM IST
Terming the decision to ban 344 fixed dose combination medicines as "arbitrary and unfair", pharma industry has said it feels let down by the government.
"The industry feels let down. We feel we were not given a fair chance. The government's order to ban 344 FDCs enblock is arbitrary and unfair," Indian drug manufacturers' association (IDMA) President S V Veerramani told reporters.
The products worth Rs 5,000 crore have been banned for manufacture, distribution and sale with immediate effect causing hardship to manufacturers and patients, he added.
In a gazette notification on March 10, the government had banned 344 FDCs including ban on manufacture, sale and distribution of fixed does combination of chlopheniramine maleate plus codiene syrup which is used in the cough syrups.
When being asked what in his opinion is the way forward, Veeramani said: "We are meeting the government and will ask them to reconsider the ban. It will impact the Make in India campaign."
This is also not in the public interest as the patients will be denied useful FDCs, he added.
"The amount of time, money and environmental impact in destroying these procedures will be huge," Federation of Pharma Entrepreneurs (FOPE) Chairman R C Juneja said.
There was no proper discussion with the industry before the ban, he added.
Several companies have approached Delhi High Court, which has granted interim stay on the government decision.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 18 2016 | 6:57 PM IST

Next Story